Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2016

01-09-2016 | Case Report

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma

Authors: Shinichi Makita, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Hideaki Kitahara, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Yukio Kobayashi, Kensei Tobinai

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30. It is highly effective for relapsed/refractory classical Hodgkin lymphoma (CHL), and has become a promising treatment option for these patients; however, approximately 25 % of patients are refractory to BV. Until now, the clinicopathologic features of CHL refractory to BV have not been well understood. Here, we report a patient with relapsed CHL with an unfavorable outcome, whose disease was primary refractory to BV and was histologically diagnosed as a transformation from mixed cellularity CHL to CD30-positive diffuse large B-cell lymphoma (DLBCL). The transformation to DLBCL showing high tumor density and high proliferative activity (Ki67 index >90 %) was possibly related to the primary refractory to BV and an aggressive clinical course, although the lymphoma was diffusely and strongly positive for CD30.
Literature
1.
Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.CrossRefPubMed
2.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.CrossRefPubMed
3.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.CrossRefPubMedPubMedCentral
4.
Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int J Hematol. 2012;96:535–43.CrossRefPubMed
5.
Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120:1470–2.CrossRefPubMed
6.
Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98:1232–6.CrossRefPubMedPubMedCentral
7.
Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, et al. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma. 2012;53:2051–3.CrossRefPubMed
8.
García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, et al. Large B-cell lymphoma with Hodgkin’s features. Histopathology. 2005;47:101–10.CrossRefPubMed
9.
Bellan C, Lazzi S, Zazzi M, Lalinga AV, Palummo N, Galieni P, et al. Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin–Reed–Sternberg cells? Diagn Mol Pathol. 2002;11:2–8.CrossRefPubMed
10.
Huang Q, Wilczynski SP, Chang KL, Weiss LM. Composite recurrent Hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces. Am J Clin Pathol. 2006;126:222–9.CrossRefPubMed
11.
Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376–84.CrossRefPubMedPubMedCentral
12.
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194–204.CrossRefPubMed
13.
Gan PP, McCarroll JA, Po’uha ST, Kamath K, Jordan MA, Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010;9:1339–48.CrossRefPubMed
14.
Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin Cancer Res. 1999;5:3920–7.PubMed
15.
Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, et al. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin’s lymphoma after rituximab therapy. Cancer Sci. 2009;100:54–61.CrossRefPubMed
16.
Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394–402.CrossRefPubMed
17.
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33:3750–8.CrossRefPubMed
Metadata
Title
Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma
Authors
Shinichi Makita
Akiko Miyagi Maeshima
Hirokazu Taniguchi
Hideaki Kitahara
Suguru Fukuhara
Wataru Munakata
Tatsuya Suzuki
Dai Maruyama
Yukio Kobayashi
Kensei Tobinai
Publication date
01-09-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2018-y

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue

Original Article

Prognostic impact of RUNX1 and ETV6 gene copy number on pediatric B-cell precursor acute lymphoblastic leukemia with or without hyperdiploidy

Progress in Hematology

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside

Case Report

Long-term survival of donor bone marrow multipotent mesenchymal stromal cells implanted into the periosteum of patients with allogeneic graft failure

Original Article

A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists

Progress in Hematology

Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma

Case Report

Two cases of primary adult T-cell leukemia/lymphoma of bone: case reports and a review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits